Gene therapy for aging

Gene therapy for aging is the delivery of genetic material to a large fraction of an adult's cells with the aim of changing the trajectory of aging itself rather than treating a single inherited disease. The methods are those of ordinary Somatic gene therapy; the ambition is larger. The same viral vectors and nucleic-acid payloads are aimed at systemic targets such as telomere maintenance, muscle mass, or epigenetic state, and given to people who are not sick by any current definition. As of 2026 the animal results are real, and the human record consists almost entirely of unregulated self-experimentation.

§The animal evidence

The founding result came from telomerase. A 2012 study delivered the mouse TERT gene in an adeno-associated viral vector to adult mice and reported extended median lifespan, with a larger effect in animals treated at one year of age than at two, and without an observed increase in cancer incidence.¹ The lack of an observed cancer increase is the surprising part, because telomerase reactivation is a near-universal feature of tumours, and the finding has not been reproduced widely enough to settle the safety question. How much it means depends on the broader argument covered under Telomeres and telomerase: in several respects telomere attrition is a weaker driver of human aging than of mouse aging.

Two other targets recur. Klotho, a protein whose loss in mice produces a syndrome resembling accelerated aging and whose overexpression extends mouse lifespan,² has been pursued both as gene therapy and as injected protein; a study in aged rhesus monkeys reported cognitive improvement after peripheral klotho administration, in small numbers and without long-term follow-up. Follistatin blocks myostatin signalling and reliably increases muscle mass when delivered by AAV to mice and monkeys; early-phase trials in muscular dystrophy have reported modest and inconsistent functional change,³ and added muscle mass does not translate simply into added strength, the issue treated in Myostatin inhibition.

The newest line of work delivers reprogramming factors instead of a single protein. Vectors carrying OSK, the three-factor subset of the Yamanaka factors that omits the oncogene MYC, have been reported to extend remaining lifespan in mice treated in old age: one study gave an inducible AAV-OSK system to male mice aged 124 weeks and reported a 109% increase in median remaining lifespan, a result that has not been independently replicated.⁴ In 2026 an OSK construct entered a registered human trial aimed at a disease rather than at aging: Life Biosciences' ER-100, an AAV vector carrying doxycycline-controlled OSK injected into one eye, began an open-label phase 1 safety study in glaucoma and ischaemic optic neuropathy.⁵ This work sits at the intersection of gene therapy and Epigenetic reprogramming; the dosing and duration questions are those of Partial reprogramming.

Mice are not the hard case

A mouse lives under thirty months, weighs thirty grams, and can receive a vector dose per kilogram that is impossible to manufacture for an adult human. Every result in this section is a result about a small, short-lived, inbred animal treated in a specific-pathogen-free facility.

§Why aging is a difficult target

Gene therapy works best where a single defective gene in a reachable tissue causes a defined disease. Aging meets none of those conditions.

No single target. The processes catalogued as Hallmarks of aging are numerous and partly independent. A construct that addresses telomere length leaves the others untouched, so proposals in this space tend toward multi-gene combinations, and each added gene brings immunological and manufacturing complexity.

Delivery. AAV reaches the liver efficiently and most other tissues poorly, carries a payload limit of about five kilobases, and provokes an immune response that prevents redosing with the same capsid. A substantial share of adults already carry neutralizing antibodies to common serotypes and are ineligible. Engineered capsids and non-viral routes such as Lipid nanoparticles address parts of this, but no delivery system currently reaches a majority of cells in a majority of tissues in an adult.

Permanence. An AAV genome persists episomally in non-dividing cells for years and cannot be withdrawn. For a transgene that promotes growth, blocks a tumour suppressor, or reactivates telomerase, the lack of an off switch is a serious safety problem. Regulatable systems and transient mRNA delivery answer it, but they require repeated administration, and immunity tends to close that route.

Risk-benefit. High-dose systemic AAV has caused severe hepatotoxicity and deaths in trials for serious childhood diseases. That risk is defensible when the alternative is a fatal disorder. It is not defensible for a healthy sixty-year-old seeking a probabilistic benefit decades later. No regulator has an approval pathway for the indication either, the same structural obstacle described under Geroscience hypothesis and in the TAME proposal.

§Unregulated human use

Because no controlled trial for aging exists, most human use has happened outside conventional oversight.

In September 2015 the chief executive of the company BioViva, Elizabeth Parrish, received two gene therapies outside the United States, reportedly in Colombia: follistatin, a myostatin inhibitor, injected into muscle, and an intravenous viral vector carrying telomerase.⁶ BioViva later announced, by press release, lengthening of her leukocyte telomeres measured by a commercial assay. The result was not published in a journal, the assay is noisy, and a single person cannot constitute a study.

In 2019 Libella Gene Therapeutics offered an AAV telomerase gene therapy at a clinic in Zipaquirá, Colombia, at $1 million per dose.⁷ The pay-to-participate structure inverts the ethics of clinical research by charging subjects for an unproven intervention. Its registry entries, each for five participants, were last updated in 2019 and report no results.⁵

Minicircle, a Delaware-registered startup, doses volunteers in Próspera, a special economic zone on the Honduran island of Roatán with its own regulatory framework, whose legal standing Honduras has contested since its Congress voted in 2022 to repeal the law behind such zones. The company recruited volunteers in 2022 for a plasmid follistatin gene therapy, at one point asking them to buy an NFT to take part.⁸ That study enrolled 43 people between August 2022 and August 2023, was registered only in May 2024, after it had finished, and has posted no results.⁵ In September 2023 the longevity entrepreneur Bryan Johnson received the therapy, then listed at about $25,000 per treatment, on Roatán; Minicircle had published no trial data.⁹ Plasmid delivery is less persistent than AAV, which reduces some risks. In 2025 the company began two further single-arm studies, of a klotho plasmid and of klotho combined with follistatin, each enrolling 14 people; as of October 2026 neither had posted results. A second company, Unlimited Biotechnology, began an open-label phase 1/2a at a Roatán clinic in June 2026, combining an AAV9 follistatin vector with a VEGF plasmid for age-related muscle decline.⁵

These ventures share a pattern: jurisdiction shopping, no control groups, surrogate endpoints chosen after the fact, and outcomes announced by press release. The later ventures register on ClinicalTrials.gov, which makes their designs visible but adds no control group. The ventures generate little usable knowledge and raise regulatory scrutiny for researchers doing the work properly.

§What a legitimate path would look like

The most plausible route runs through narrow indications where a systemic genetic intervention is already defensible. Gene therapies targeting the APOE4 variant in carriers at high risk of Alzheimer's disease have entered early-phase trials, and one-time editing of PCSK9 to lower lifelong cholesterol, using Base editing delivered in lipid nanoparticles and first shown to work durably in non-human primates,¹⁰ is the closest existing test of a durable genetic intervention given for prevention rather than rescue. Neither is marketed as an aging therapy, but both would set the precedents an aging therapy needs: acceptable risk in relatively healthy adults, a durable effect from a single administration, and a regulatory framework for prevention.

Progress also depends on measurement. Without an accepted biomarker of aging a trial cannot read out in less than a decade, and neither an Epigenetic clocks shift nor an improvement in a composite age score is currently sufficient for approval.

§Outlook

The near-term question is whether any of the candidate constructs are worth the delivery risk, a narrower question than whether aging can be treated genetically at all. Telomerase carries an unquantified cancer liability; follistatin adds muscle of uncertain functional value; reprogramming factors carry dedifferentiation and teratoma risk that has been demonstrated in mice. Combining them multiplies these problems instead of averaging them out.

If the field does mature, its main constraint may be economic rather than biological. One-time gene therapies for rare disease already carry prices in the millions, and a therapy intended for everyone above sixty would face a manufacturing and distribution problem of a different order, the concern argued out under Access and inequality.

§See also

• Somatic gene therapy
• AAV vectors
• Epigenetic reprogramming
• Telomeres and telomerase
• Myostatin inhibition
• Hallmarks of aging
• Senolytics
• Geroscience hypothesis

§References

Footnotes

1. paperBernardes de Jesus, B. et al. "Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer." EMBO Molecular Medicine, 2012.↩Laboratory mice have far longer telomeres than humans and express telomerase in more tissues, so the model may not transfer.

2. paperKurosu, H. et al. "Suppression of aging in mice by the hormone Klotho." Science, 2005.↩A transgenic overexpression model rather than a delivered therapy: the mice carried the extra klotho from conception.

3. paperMendell, J.R. et al. "A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy." Molecular Therapy, 2015.↩An open-label early-phase trial in a small number of men with Becker muscular dystrophy, with no placebo group.

4. paperMacip, C. C. et al. "Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice." Cellular Reprogramming, 2024.↩Male mice only, treated from 124 weeks of age; the 109% figure is for median remaining lifespan, not total lifespan.

5. trialClinicalTrials.gov records NCT04133649 (Libella, AAV-hTERT), NCT06411366 (Minicircle, follistatin plasmid), NCT07216781 and NCT07285629 (Minicircle, klotho and klotho-follistatin plasmids), NCT07443826 (Unlimited Biotechnology, AAV9-follistatin with VEGF plasmid), and NCT07290244 (Life Biosciences, ER-100), checked October 2026.↩ ↩² ↩³ ↩⁴All are single-arm or non-randomised and unmasked; none had posted results at the time checked.

6. newsRegalado, A. "A Tale of Do-It-Yourself Gene Therapy." MIT Technology Review, 14 October 2015. https://www.technologyreview.com/2015/10/14/165802/a-tale-of-do-it-yourself-gene-therapy/↩The magazine could not confirm many details: Parrish would not name the country or the doctor, and Colombia comes from people involved with the company.

7. newsSwain, F. "Buyer beware of this $1 million gene therapy for aging." MIT Technology Review, 6 December 2019. https://www.technologyreview.com/2019/12/06/131657/buyer-beware-of-this-1-million-gene-therapy-for-aging/ ↩

8. newsClarke, L. "This biohacking company is using a crypto city to test controversial gene therapies." MIT Technology Review, 13 February 2023. https://www.technologyreview.com/2023/02/13/1068330/minicircle-prospera-honduras-biohacking-follistatin-gene-therapy/ ↩

9. newsRoyle, O. R. "Bryan Johnson is being used as a human guinea pig in unproven gene therapy injections worth $25,000 a pop in an island off Honduras." Fortune, 21 December 2023. https://fortune.com/2023/12/21/bryan-johnson-human-guinea-pig-unproven-tests-reprogram-human-genes-follistatin-roatan-island-honduras↩Reports that Minicircle did not charge Johnson; his claimed results come from his own posts and from Bloomberg, not from a study.

10. paperMusunuru, K. et al. "In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates." Nature, 2021. ↩